Marken Presentation: Advanced Therapies 2.0: Manufacturing and Supply Chain Considerations for the 21st Century
Friday, May 31, 2024 10:15 AM - 10:45 AM
Exhibit Hall - Theatre A
Global Showcase Presentation
Presenter
Advanced therapy modalities such as cell & gene therapies, nucleic acid therapies, personalized cancer vaccines, and more, require specialized bioreactors for advanced manufacturing and advanced logistics solutions to ensure they are delivered with full traceability and chain of custody. In recent times, these therapies have been showing curative potential for the treatment of cancer and rare disease alike, but in some cases, their price has skyrocketed to as high as $3.2M per dose.
How can we democratize these therapies further? Join us as we delve into some of the manufacturing and supply chain considerations that can bring down the cost by de-risking the manufacturing and logistics, ensure real-time visibility and flawless cold chain management, and to ultimately get the therapies to the patients who so desperately need them safely.
Session Objectives:
• Understanding advanced therapy supply chain bottlenecks
• Understanding the cost drivers for advanced therapies
• Understanding the role of digital sensing, data loggers and real-time visibility tools
• Understanding strategies for reducing uncertainty and improving turnaround times for cold chain logistics
• What is the future vision (Advanced Therapies 2.0) for the manufacturing, storage, and distribution these life-altering therapies
- Rohin Krishnan Iyer, Senior Director, Global Cell and Gene Therapy Operations, Advanced Therapies Division, Marken A UPS Company, Canada
Advanced therapy modalities such as cell & gene therapies, nucleic acid therapies, personalized cancer vaccines, and more, require specialized bioreactors for advanced manufacturing and advanced logistics solutions to ensure they are delivered with full traceability and chain of custody. In recent times, these therapies have been showing curative potential for the treatment of cancer and rare disease alike, but in some cases, their price has skyrocketed to as high as $3.2M per dose.
How can we democratize these therapies further? Join us as we delve into some of the manufacturing and supply chain considerations that can bring down the cost by de-risking the manufacturing and logistics, ensure real-time visibility and flawless cold chain management, and to ultimately get the therapies to the patients who so desperately need them safely.
Session Objectives:
• Understanding advanced therapy supply chain bottlenecks
• Understanding the cost drivers for advanced therapies
• Understanding the role of digital sensing, data loggers and real-time visibility tools
• Understanding strategies for reducing uncertainty and improving turnaround times for cold chain logistics
• What is the future vision (Advanced Therapies 2.0) for the manufacturing, storage, and distribution these life-altering therapies
SPONSORED BY:
Rohin Iyer
Senior Director, Global Cell and Gene Therapy Operations, Advanced Therapy Division
Marken A UPS Company
Speaker
Senior Director, Global Cell and Gene Therapy Operations, Advanced Therapy Division
Marken A UPS Company
Speaker